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ABSTRACT
Objectives: Post-operative nausea and vomiting (PONV) is a frequently experienced complication following laparoscopic cholecystectomy. This study 
was planned to compare the antiemetic efficacy of palonosetron with ondansetron in patients undergoing laparoscopic cholecystectomy.
Methods: A total of 100 patients undergoing laparoscopic cholecystectomy were randomized into two groups. Group O (n=50) received ondansetron 
(8 mg) and Group P (n=50) received palonosetron (0.075 mg) 3 min before induction of anesthesia. Post-operatively, patients were assessed for the 
occurrence of nausea, retching, or vomiting at 0–2, 2–6, 6–24, 0–24, and 24–48 h time intervals. The overall incidence of PONV in time frame (0–48 h) 
was determined. The need of rescue antiemetic, side effect profile, and patient satisfaction scores were also assessed.
Results: The incidence and severity of nausea at all the time intervals were comparable in the two groups. The incidence of vomiting was significantly 
less in Group P as compared to Group O in 0–2 h (2% vs. 14%, p=0.027) and 0–24 h time intervals (10% vs. 30%, p=0.012). The overall incidence of 
PONV in 0–48h was lesser in Group P as compared to Group O (28% vs. 50%, p=0.024). Rescue antiemetic was required in greater number of patients 
in Group O as compared to Group P (p=0.038). Side effect profile and patient satisfaction scores were comparable in the two groups.
Conclusion: Palonosetron is better than ondansetron in lowering the overall incidence of PONV in 0–48 h time interval, in patients undergoing 
laparoscopic cholecystectomy.
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INTRODUCTION
Pain, nausea, and vomiting are major perioperative concerns of 
patients [1]. Post-operative nausea and vomiting (PONV) is not only an 
unpleasant and distressing experience for the patient but also in severe 
cases may cause problems such as dehydration, electrolyte imbalance, 
suture dehiscence, bleeding, and esophageal rupture [2,3]. The 
incidence of PONV ranges between 10 and 78% depending on patient-
specific, anesthesia, and surgery-related factors [4].
PONV has a complex multifactorial etiology involving multiple 
receptor pathways at peripheral, central, or both sites [5]. Role of 
several neurotransmitters such as serotonin, dopamine, muscarine, 
acetylcholine, neurokinin-1, histamine, and opioids has been 
implicated in PONV [5]. Antiemetic drugs that include serotonin 
5-HT3 (5-hydroxytryptamine-3) receptor antagonists, dopamine 
receptor antagonists, histamine H2 receptor antagonists, anticholinergic 
agents, and corticosteroids have been tried effectively in the prevention 
of PONV [6]. In comparison to other antiemetics, 5-HT3 receptor 
antagonists are effective antiemetic drugs associated with fewer side 
effects such as sedation or extrapyramidal symptoms [7]. Ondansetron, 
a first-generation 5-HT3 receptor antagonist [8], is widely used as an 
antiemetic, in varied post-operative settings and clinical situations [7]. 
Palonosetron, a second-generation 5-HT3 receptor antagonist, due 
to its unique pharmacodynamic characteristics has a higher receptor 
affinity, greater potency, and longer duration of action as compared to 
other 5-HT3 antagonists [9].
Studies comparing palonosetron with ondansetron for PONV 
prophylaxis in patients undergoing laparoscopic cholecystectomy 
for 48-h duration are sparse, and most comparisons are for 24 h. We 
undertook the current study to evaluate the efficacy of palonosetron for 
the prophylaxis of PONV for 48 h and compare it to that of ondansetron 
in patients undergoing laparoscopic cholecystectomy. The primary 
outcome measure was the overall incidence of PONV in 0–48 h, and the 
secondary outcome measures were incidence and severity of nausea, 
incidence of vomiting, number of patients requiring rescue antiemetic, 
side effects, and patient satisfaction rate.
METHODS
This prospective, randomized, double-blind study was conducted in a 
tertiary care hospital, New Delhi, India, after obtaining approval from 
the hospital ethics committee. The study has been registered with the 
Clinical Trials Registry, India (CTRI/2017/08/009295).
A total of 100 patients, in the age group of 18–60 years, of either 
sex, weighing 40–80 kg, American Society of Anesthesiologists 
physical status classification I–II, scheduled to undergo laparoscopic 
cholecystectomy under general anesthesia with duration of surgery 
<2 h were included in the study. The exclusion criteria included 
menstruating, pregnant, or lactating women; hypersensitivity to study 
medication; previous history of PONV or motion sickness; receiving 
drugs with known emetic or antiemetic effect within 24 h before 
surgery; having received cancer chemotherapy within 4 weeks or 
emetogenic radiotherapy within 8 weeks; smokers, obese, diabetes, 
psychiatric diseases, or gastrointestinal tract disease; alcohol or 
substance abuse; and patients requiring continuous gastric suction in 
post-operative period.
Patients were advised to fast overnight and received alprazolam 
(0.25 mg) tablet as premedication night before and 2 h before surgery 
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with a sip of water. Patients were randomly allocated into two groups, 
ondansetron group (Group O, n=50) or palonosetron group (Group P, 
n=50) using lottery method. Concealment of allocation was done using 
sequentially numbered, opaque, sealed envelopes that were numbered 
in advance, and were sequentially opened after the participant’s name, 
and other details were written on the appropriate envelope. The study 
medication was administered in a double-blind manner, and neither 
patient nor observer were aware of the drug administered, either 
before or during the observation period following surgery. Group O 
patients received 8 mg (4 ml) of ondansetron, while Group P patients 
received 0.075 mg (1.5 ml) palonosetron diluted up to 4 ml with normal 
saline, intravenously.
In the operation theater, standard monitors (electrocardiogram, non-
invasive blood pressure, and pulse oximeter) were applied and baseline 
readings noted. Intravenous access was secured using 18-gauge 
intravenous cannula. 3 min before induction of anesthesia, study drug, 
depending on the group allocation, was administered intravenously. 
Following induction of anesthesia with fentanyl (2 μg/kg), thiopentone 
(5 mg/kg), an muscle relaxant vecuronium bromide (0.1 mg/kg) was 
given to facilitate tracheal intubation. Anesthesia was maintained with 
isoflurane in a mixture of oxygen and nitrous oxide. Nasogastric tube 
was inserted for gastric decompression, as it was a surgical requirement.
During surgery, intra-abdominal pressures following carbon dioxide 
gas insufflation were maintained between 10 and 12 mm Hg. The 
end-tidal carbon dioxide concentration was maintained between 35 
and 40 mm Hg throughout the surgery. For post-operative analgesia, 
diclofenac (75 mg) IV was given and surgical port sites were infiltrated 
with 0.25% bupivacaine at the completion of surgery. Nasogastric 
tube was removed following gastric decompression, and residual 
neuromuscular blockade was reversed with neostigmine and 
glycopyrrolate. Hemodynamic monitoring was done throughout the 
surgery. Any episode of hypotension (systolic blood pressure <90 
mm Hg) or hypoxia (SpO2 <95%) was noted and treated accordingly. 
Post-operatively, patients were assessed for the occurrence of nausea, 
retching, or vomiting at 0–2, 2–6, 6–24, 0–24, and 24–48 h time 
intervals. Patients’ complaining of severe nausea, retching, or vomiting 
was given 10 mg IV metoclopramide, a dopamine antagonist [10] as 
rescue antiemetic. Side effects, if any, such as dizziness, headache, and 
constipation were also evaluated.
Nausea was defined as an unpleasant sensation with awareness of the 
urge to vomit. Retching was defined as labored, spasmodic, rhythmic 
contractions of the respiratory and abdominal muscles, without the 
expulsion of gastric contents, and vomiting was defined as forceful 
expulsion of stomach contents from the mouth [11]. For the purpose 
of this study, retching was considered as vomiting episode. Nausea was 
graded on a four-point scale (0: No nausea; 1: Mild nausea; 2: Moderate 
nausea; and 3: Severe nausea) [7]. The overall incidence of PONV 
(cumulative incidence of nausea, retching, and vomiting) at 0–48 h was 
determined at the end of the study. Patients were also asked to rate 
their satisfaction of PONV control, at the end of 48 h, using a 5-point 
scale (1 = very satisfied; 2 = somewhat satisfied; 3 = neither satisfied 
nor dissatisfied; 4 = somewhat dissatisfied; and 5 = very dissatisfied).
Statistics
Previous studies [7,12] found the incidence of PONV to be 66% in 
ondansetron group and 42% in palonosetron group. Based on these 
figures, sample size was calculated by a power analysis using one-
tailed, alpha value (0.05) and power 80%, and it was estimated that 
a minimum of 48 patients per group would be required to show 25% 
difference in the incidence of PONV between the groups. In total, 
100 patients were enrolled and they were randomly assigned into two 
study groups of 50 each.
Statistical analysis was performed using SPSS for Windows, version 16.0 
(SPSS Inc., Chicago, IL, USA). Continuous variables - age, weight, and 
duration of surgery - are presented as mean±standard deviation. 
Categorical variables - ASA class, sex distribution, nausea incidence and 
grade (severity), vomiting incidence, overall PONV, number of patients 
requiring rescue antiemetic, side effects, and patient satisfaction 
rate - are presented as absolute numbers or percentages.
The comparisons of normally distributed continuous variables between 
the groups were performed using independent Student’s t-test. Nominal 
categorical data between the groups were compared using Chi-square 
test or Fisher’s exact test as appropriate. Patient satisfaction ratings 
were compared on the basis of Student independent t-test. For all 
statistical tests, “p<0.05 was taken to indicate a significant difference.”
RESULTS
A total of 120 patients were assessed for eligibility. Of these, 20 patients 
were excluded, as 15 patients did not meet inclusion criteria and 
5 patients declined to participate. Remaining 100 patients were 
randomized into the two study groups.
There were no differences in age, weight, sex, ASA class, and mean 
duration of surgery between the two groups (Table 1).
The incidence and severity of nausea were comparable in the two 
groups at all the time intervals as shown in Table 2. The incidence of 
vomiting was significantly less in Group P as compared to Group O 
in 0–2 h (p=0.027) and 0–24 h (p=0.012) (Table 2). However, it was 
comparable at all other time intervals, in the 48-h post-operative 
period, in the two groups. The overall incidence of PONV (cumulative 
incidence of nausea, retching, and vomiting) in 0–48 h was significantly 
lower in palonosetron group (28%) as compared to ondansetron group 
(50%, p=0.024). Rescue antiemetic was required in greater number 
of patients in Group O (17/50 patients) as compared to Group P 
(8/50 patients, p=0.038) (Table 2).
No patient in any group had any episode of oxygen desaturation or 
hypotension. The incidence of side effects such as headache, dizziness, 
and constipation in ondansetron and palonosetron groups (4%, 4%, 
and 0% and 0%, 4%, and 4%, respectively) was comparable. Patient 
satisfaction ratings were also comparable in the two groups (p=0.070), 
(Table 2).
DISCUSSION
Laparoscopic surgery involves the creation of a pneumoperitoneum; 
this increases the risk of PONV due to the stimulation of 
mechanoreceptors and increased serotonin (5 HT) synthesis [13]. The 
incidence of PONV following laparoscopic surgery is reported to be as 
high as 70–85% [14,15]. Apart from the complications [2,3] associated 
with PONV, patients find it extremely distressing, making it important 
to prevent its occurrence for patient comfort and well-being. Among 
the antiemetic drugs given for PONV prophylaxis, 5-HT3 receptor 
antagonists are widely used drugs due to a favorable side effect 
profile [7]. The antiemetic efficacy of ondansetron is well established 
for both PONV prophylaxis and treatment [16]. Palonosetron due to 
its longer half-life (40 h) as compared to ondansetron (3.5–5.5 h) may 
provide for PONV prophylaxis for a longer duration of time that may 
extend to 48 h [16].







Age (year) 35.98 (10.11) 35.16 (9.97) 0.699
Weight (kg) 59.78 (7.88) 58.14 (8.90) 0.332
Sex (M/F) 10/40 7/43 0.424
ASA class (I/II) 44/6 42/8 0.564
Surgery duration (min) 57.88 (15.56) 57.66 (17.07) 0.473
Data are expressed as mean (±SD) or numbers. P<0.05 is statistically significant. 
SD: Standard deviation
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In our study, we found the overall incidence of PONV (0–48 h) to be 
significantly lower in palonosetron group (14/50 patients, 28%) as 
compared to ondansetron group (25/50 patients, 50%, p=0.024) with 
fewer patients in palonosetron group requiring a rescue antiemetic 
(p=0.038). Similarly, other authors have also found a lower incidence 
of PONV with palonosetron as compared to ondansetron. Park 
and Cho found a significantly lower incidence of PONV in 0–24 h 
with palonosetron as compared to ondansetron (42.2% vs. 66.7%, 
respectively) in patients undergoing gynecological laparoscopic 
surgery [12]. In patients, receiving fentanyl-based patient-controlled 
analgesia after thyroidectomy, incidence of PONV during the 24 h 
post-operative period was lower in the palonosetron group than in 
the ondansetron group (42% vs. 62%, p=0.045) although investigators 
in this study had given ondansetron 8 mg bolus and added 16 mg to 
the IV PCA mixture, while palonosetron was given as a single bolus 
dose [7]. The incidence of PONV (0–24 h) following laparoscopic 
cholecystectomy was significantly lower in patients receiving 
palonosetron (20%) as compared to ondansetron (50%), but in this 
study, the investigators had used a lower dose of 4 mg ondansetron as 
compared to 8 mg in our study [17]. In patients undergoing bilateral 
laparoscopic tubal ligation as day care surgery, palonosetron (0.075 mg) 
was found to be superior to ondansetron (8 mg) when administered as 
single pre-induction IV dose with an overall incidence of nausea and 
vomiting (0–72 h) to be significantly higher in the ondansetron group 
as compared to palonosetron group (20% and 13.33% vs. 6.67% and 
3.33%, respectively) [18]. In variance with our results as well as those 
of other studies [7,12,17,18], Laha et al. did not find the antiemetic 
efficacy of palonosetron (0.075 mg) to be superior to ondansetron 
(4 mg) for preventing PONV during the first 24 h after laparoscopic 
cholecystectomy [16].
We found the incidence and severity of nausea to be comparable in both 
the groups at all the time intervals. Some investigators have reported 
a significantly lower incidence of nausea (24 h) with palonosetron as 
compared to ondansetron (16% vs. 24%) but may be this difference 
was due to a lower dose of ondansetron 4 mg used in their study, as 
compared to 8 mg used in ours [17]. Shadangi et al. found the overall 
incidence of nausea (24 h) to be much less with palonosetron as 
compared to ondansetron (16.7% vs. 43.4%, p=0.006) [19]. In their 
study, male-to-female ratio was 1 in ondansetron group and 1.3 in 
palonosetron group. The palonosetron group having more males than 
females could have influenced their result, female gender being a risk 
factor for PONV [19].
In our study, the incidence of vomiting was significantly less in Group P 
as compared to Group O in 0–2 h (2% vs. 14%, p=0.027) and 0–24 h 
time intervals (10% vs. 30%, p=0.012). However, it was comparable 
at all other time intervals, in the 48-h post-operative period, in the 
two groups. Bajwa et al., in their study, found the overall incidence of 
vomiting (0–72 h) to be 13.33% in ondansetron group and 3.33% in 
palonosetron group [18]. In their study, during the 6–12 h period, the 
incidence of vomiting was significantly less in palonosetron group as 
compared to ondansetron group [18]. In a meta-analysis, the efficacy 
of palonosetron was found to be better than ondansetron in preventing 
vomiting, at various time intervals, 0–2 h (RR, 0.45; 95% CI, 0.26–0.78), 
2–6 h (RR, 0.74; 95% CI, 0.39–1.40), and 6–24 h (RR, 1.20; 95% CI, 
0.55–2.64) during the first 24-h post-operatively after laparoscopic 
surgery [20].
A rescue antiemetic was required in greater number of patients in 
Group O (17/50 patients [34%]) as compared to Group P (8/50 patients 
[16%], p=0.038), in our study. Other authors have also found the need 
of rescue antiemetics to be significantly higher in patients receiving 
ondansetron as compared to palonosetron [7,17]. The occurrence 
of side effects such as headache, dizziness, and constipation was 
comparable in both the study groups. Other authors have also found the 
safety profile of palonosetron and ondansetron to be comparable [19] 
Likewise, Liu et al., in a meta-analysis, to evaluate the efficacy and 
safety of palonosetron and ondansetron in preventing PONV in patients 
undergoing laparoscopic surgery found no significant differences in 
side effects between palonosetron and ondansetron [20].
Although we found palonosetron to be better than ondansetron in 
lowering the overall incidence of PONV in 0–48 h time interval, the 
patient satisfaction ratings in both the groups were comparable. 
Likewise, Park and Cho also found comparable patient satisfaction rates 
with the use of these two drugs for PONV prophylaxis [12].
Our study has several limitations. First, we did not have a control 
group, as we did not want to deprive patients’ undergoing laparoscopic 
cholecystectomy of antiemetic prophylaxis, knowing the high incidence 
of PONV following this surgery. Second, we compared the efficacy of 
palonosetron and ondansetron on the basis of known optimal dosages, 
without knowledge of equipotent doses. Third, nausea and patient 
satisfaction score were subjective rating scales that may depend on the 
literacy levels of patients.
To conclude, palonosetron has better antiemetic efficacy than 
ondansetron in lowering the overall occurrence of PONV in 0–48 h time 
interval, in patients undergoing laparoscopic cholecystectomy with 
lesser number of patients requiring a rescue antiemetic. Its side effect 
profile and patient satisfaction rating are similar to ondansetron.
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